Real-world data from four European countries shows advanced soft tissue sarcoma is primarily treated with older therapies, indicating an unmet need for novel survival-prolonging treatments.
Older therapies predominate in advanced STS across Europe; leaves open whether novel agents can improve survival and warrants prospective trials.
In real-world clinical practice, advanced STS is most commonly treated with older therapies in the United Kingdom, Spain, Germany, and France. New therapies that improve overall survival in advanced STS are needed.
No takes yet. Share an insight, caveat, or question.
Nagar et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: